Clinical trials: Type 2 Diabetic
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Primary Objective: The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c)…
- Trial name
- NCT01476475
- Testing
- Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
- Where
- 70 sites in United States, Chile and 11 more
- Volunteers
- 323 people
- Sponsor
- Sanofi
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Diabetes Mellitus Type 2
Impact of Pharmaceutical Care in Diabetics Patients
The monitoring of diabetics by the pharmacist may contribute to the effectiveness of drug treatment and to improve their quality of life. This study will measure the impact of pharmacotherapeutic follow-up in diabetic patients.
- Trial name
- IPCD (NCT01580904)
- Testing
- Intervention: Pharmaceutical Care
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Universidade Estadual da Paraiba
Diabetes Mellitus, Type 2
Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients
Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients.
- Trial name
- NCT02099838
- Testing
- Pioglitazone and Metformin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Huazhong University of Science and Technology
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Insulin Sensitivity
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
- Trial name
- Eritoran2 (NCT02267317)
- Testing
- Eritoran, D5W
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Kidney Disease, Nephropathy
VA NEPHRON-D: Diabetes iN Nephropathy Study
Diabetes is the leading cause of end-stage renal disease (ESRD) in the United States. The overall rate of ESRD secondary to diabetes has risen 68% since 1992.
- Conditions
- Kidney Disease, Nephropathy, Type 2 Diabetes
- Trial name
- VA NEPHRON-D (NCT00555217)
- Testing
- losartan, lisinopril
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 1,448 people
- Sponsor
- US Department of Veterans Affairs
Diabetes Mellitus, Type 2
Insulin Glulisine in Type 2 Diabetic Patients
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled…
- Trial name
- Basal Plus (NCT00360698)
- Testing
- Insulin Glargine, Glimepiride, Insulin Glulisine
- Where
- 3 sites in United States, Russia and 1 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of repaglinide plus metformin as initial treatment compared to repaglinide alone in Chinese subjects with type 2…
- Trial name
- NCT00819741
- Testing
- repaglinide, metformin
- Where
- 17 sites in China
- Volunteers
- 433 people
- Sponsor
- Novo Nordisk A/S
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic
Tooth Replacement
Dental Implant Study Comparing Two Types of Metals Used for Dental Implants
The purpose of this research study is to compare the healing differences of two metals (trabecular vs. standard titanium) that are used for dental implants.
- Trial name
- ZMU (NCT01714024)
- Testing
- Zimmer Trabecular Metal Test Cylinder, Zimmer Titanium Test Cylinder
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric…
- Trial name
- RITE (NCT02008942)
- Testing
- PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- PLx Pharma